The Possible Therapeutic Role of Intravenous Lipid Emulsion in Acute Aluminium Phosphide Poisoning: A Randomized Controlled Clinical Trial

Phase 2

Recruiting

• Conditions: Injury, Occupational Diseases, Poisoning

• Registration Number: PACTR202102767216677
• Lead Sponsor: Hafsa Salah Gheat

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-19
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

Patients aged = 12 years old.
Either gender male or female.
Symptomatic acute ALP poisoning.
Diagnosis will be made on the basis of:
1. The suggestive clinical manifestations due to and following shortly after exposure to ALP.
2. Reliable identification of the compound based on the container brought by patient attendants
3. Biochemical detection of phosphine gas in gastric aspirate (silver nitrate test)

Exclusion Criteria

Patients less than 12 years old.
Pregnant and lactating women.
Patients with mixed ingestion or exposure.
Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure).
Patients treated for acute phosphide poisoning in any medical center before admission.
Patient with hyperlipidemia (serum triglyceride levels exceeds 400 mg/dL)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality

Secondary Outcome Measures

Name	Time	Method
Mean arterial blood pressure<br>Need for intubation.<br>Need for mechanical ventilation.<br>The total dose of vasopressor needed.<br>Duration of hospital stay.<br>Serum lactate levels.